318 results about "Circular RNA" patented technology

The invention relates to the technical field of biological medicines, discloses application of circPDK1 protection, and particularly relates to application of a reagent for specific detection of circPDK1 in preparation of products for detection of esophageal cancer or prognosis evaluation of esophageal cancer. According to the application of the protected circular RNA in preparation of the esophageal cancer detection product, the circular RNA is circPDK1, and the nucleotide sequence of the circular RNA is shown as SEQ ID NO: 1. Experiments prove that circPDK1 is highly expressed in esophageal cancer tissues, growth, proliferation and migration of esophageal cancer cells are promoted, occurrence of esophageal cancer is promoted, knock-down of the circular RNA can significantly inhibit growth, proliferation and migration of esophageal cancer tumors, and the average survival time of esophageal cancer patients with low circPDK1 expression is longer than that of esophageal cancer patients with high circPDK1 expression. And a new research direction is provided for esophageal cancer detection, treatment and prognosis.

The application discloses a kind of based on shared unit's circular RNA and the construction method of disease association prediction model, prediction system and prediction method, and the association prediction is realized by the circular RNA and the disease association prediction model constructed, comprising: based on known association dataset constructs circular RNA meta-path network, circular RNA similarity network, disease meta-path network and disease similarity network, the feature extraction of the aforementioned network respectively obtains circular RNA similarity feature, circular RNA meta-path feature, disease similarity feature and disease meta-path feature;Similarity feature and meta-path feature are simultaneously input into shared unit;The similarity feature output by shared unit is input into multilayer perception machine to carry out the association prediction of circular RNA and disease and update model parameter.Share unit is designed for model, and the similarity network and meta-path network of circular RNA and disease are constructed, and potential cross-view information is captured in the process of multi-view feature fusion, so as to improve the prediction performance of model.

The present invention provides nucleic acids and methods for making circular RNAs (circRNAs), compositions comprising circular RNAs, and methods of use thereof. The present invention uses optimized self-splicing T4 bacteriophage td gene (T4td) intron sequences to produce circular RNAs. The optimized T4td intron sequences described herein mediate efficient circularization of a linear RNA sequence.

Provided is an application of a circular RNA in the preparation of a cerebral stroke diagnosis product, belonging to the field of circular RNA medical treatments. Provided is a kit, comprising a reagent and / or test paper and / or gene chip for detecting a circular RNA-circ-Magi1. The nucleotide sequence of the circular RNA-circ-Magi1 is as shown in SEQ ID NO: 1 or SEQ ID NO: 4. Further provided is the application of a detection system for the diagnosis, assisted diagnosis or prognosis evaluation of cerebral stroke, and a detection reagent of the circular RNA-circ-Magi1 in the preparation of a kit, test paper, chip or high-throughput sequencing platform for the diagnosis, assisted diagnosis or prognosis evaluation of cerebral stroke.

An iRGD-LAMP2B-EGFP fusion protein mediated exosome surface engineering strategy is adopted, through specific recognition of iRGD peptide and integrin alpha v beta 3, corneal neovascularization core lesion cells are actively targeted, the limitation of off-target toxicity of a traditional delivery system is broken through, and a'accurate focus recognition-efficient homing 'targeted delivery normal form is established. Meanwhile, the screened circular RNA with anti-inflammatory and anti-angiogenesis dual activities is used as a core effector molecule, and in combination with an in-situ loading technology of the circular RNA molecule in an exosome parent cell, stable entrapment and targeted release of a nucleic acid drug in an exosome cavity are realized, and the problems that the nucleic acid drug is easy to degrade and poor in targeting property are solved; and dual guarantee of function specificity and delivery stability is formed. And a synergistic treatment system of a targeting exosome carrier and bifunctional circular RNA is further constructed, active molecules are accurately delivered to focus cells, and an inflammation microenvironment and an angiogenesis pathway are synchronously regulated and controlled.

The present invention provides nucleic acids and methods for making circular RNAs (circRNAs), and circular RNAs, compositions and methods of use thereof. The present invention uses selected self-splicing intron sequences (e.g., intronic sequences derived from self-splicing Group I or Group II introns) to produce circular RNAs. These self-splicing intron sequences described herein mediate efficient circularization of a linear RNA sequence.

The invention relates to a modified RNA with a synthetic cap structure and a modified coding region encoding for DNAse1 and / or DNAse1L3. The invention further relates to a saRNA and / or a circular RNA, and to a vector encoding the modified RNA. The invention also relates to a pharmaceutical composition for the use of treating a disease associated with the formation of extracellular DNA, including extracellular traps released from leukocytes, such as NETs.

Provided is a medicament for treating a disease related to motor neuron injury. The medicament comprises: a circular RNA having a circBank ID of hsa_circPTPRN2_018, and a proper diagnosis module and a drug carrier. Also provided is use of a circular RNA in preparing a medicament for diagnosing and treating a disease related to motor neuron injury.

The invention discloses a biological interpretability circular RNA automatic identification method, and belongs to the technical field of bioinformatics and computers. According to the method, sequence data is obtained from a database and preprocessed, reverse complement matching and ALU repeated element features are extracted, after the features are screened through an MRMD2.0 algorithm, a depth model combining a convolutional neural network and a bidirectional long-short-term memory network is constructed for classification training, feature contribution is analyzed through an SHAP method, and finally the model is applied to multiple scenes. According to the method, circRNA cyclization key features can be accurately captured, high-order feature representation is automatically learned to improve the classification accuracy, meanwhile, a feature biological mechanism is disclosed, multi-task migration such as circRNA and PCG distinguishing and stem cell expression prediction is achieved, and the defects of an existing algorithm in the aspects of feature representation and interpretability are overcome.

The invention relates to the technical field of biological medicines, in particular to application of hsacirc0008126 in prevention and treatment of senile osteoporosis. The invention provides the circular RNA hsacirc0008126 which can be used for regulating and controlling the mesenchymal stem cell osteogenesis and adipogenic differentiation, the mechanism of the circular RNA hsacirc0008126 on the mesenchymal stem cell osteogenesis and adipogenic differentiation is different from that of the prior art, the medicine taking the circular RNA hsacirc0008126 as the target spot can be used for treating and / or preventing osteoporosis, and the circular RNA hsacirc0008126 has important application value.

The invention provides a single-chain and double-protein-expressed circular RNA construct and a preparation method and application thereof, and the single-chain and double-protein-expressed circular RNA construct comprises 5'and 3 'introns used for realizing RNA self-splicing and cyclization as a first kind of introns; the 5'and 3 'homologous arms are used as pairing sites in RNA molecules; the exon 1 and the exon 2, which are connected after being spliced, can be spliced and connected together under the action of the first type of introns to form a complete and continuous open reading frame; an interval sequence for providing spatial and adjustment sequence structures; the IRES is used for starting translation; a glycine-serine linker as a flexible linker; a green fluorescent protein for gene expression monitoring; a luciferase for producing light by a catalytic chemical reaction. All the advantages of the double-IRES system for generating natural complete protein are reserved, and the core defect of low efficiency can be thoroughly overcome.

The application discloses a circular RNA molecule circRNA928, a coding gene thereof and an application. The nucleotide sequence of the circRNA molecule is SEQ ID No. 1 in the sequence listing. The circRNA has a regulation effect on a plant disease resistance pathway. The disease resistance function of the circRNA is of great significance to cultivation of a disease-resistant cucumber variety and is helpful to enrichment of vegetable breeding resources.

The application discloses application of NCOA7 circular RNA nanoliposome in preparation of a drug for treating premature ovarian failure or ovarian reserve function decline, and belongs to the technical field of biological medicine.The present application proves that nuclear receptor coactivator 7 (NCOA7) can relieve ovarian aging and significantly improve the ovarian function and fertility of DOR patients.The present application finds that NCOA7 circular RNA nanoliposome treatment can significantly improve the NCOA7 protein expression level of DOR female ovarian granulosa cells, improve the aging phenotype and growth rate of the DOR female ovarian granulosa cells, and has no significant influence on the biological characteristics of the ovarian granulosa cells, thereby providing a new scheme for rescuing the ovarian function and improving the fertility of DOR women.

Provided are a method for preparing scar-free circular RNA, and a recombinant nucleic acid molecule for preparing scar-free circular RNA and use thereof. The provided recombinant nucleic acid molecule based on the IRES stem-loop structure can be used for preparing a circular nucleic acid molecule completely free of exogenous sequences without altering any sequence of the IRES, thereby avoiding unpredictable effects on ribosome recruitment function caused by IRES mutations.

The present invention relates to circular RNA molecules, methods of producing circular RNA molecules, circular and non-circular intermediates thereof, and methods of treating or preventing a disease. In particular, the present invention provides circRNAs that can be prepared via chemical circularization of RNA, regardless of the circRNA sequence, length or size. Due to chemical nature of the circularization process, it allows the attachment of tags, markers, etc. after the circularization at a position in close proximity to the position where the circRNA was circularized.

Provided are small-fragment RNA derived from a circular RNA and the use thereof in the treatment of diabetic vascular diseases. The nucleotide sequence of the small-fragment RNA is CUAGCCGAAUGUUAAAAAAU. The provided small-fragment RNA has the effects of well protecting and maintaining the biological functions of vascular endothelial cells, has good structural stability, has a long half-life in vivo, and has the advantages of low effective concentration, high biological safety, etc. The provided small-fragment RNA has good application potentials in the field of clinical nucleic acid drug development, and provides a new idea for the treatment of chronic progressive vascular lesions caused by diabetes.

The invention discloses a method for screening and identifying ribosome entry sites in a short chain, which comprises the following steps of: (1) screening a short chain IRES sequence with the length of less than 100nt from an IRES database, constructing a screening library and synthesizing; (2) constructing a screening vector containing double reporter genes, cloning the short-chain IRES into a linearized screening vector, and generating circular RNA which only depends on the short-chain IRES sequence to recruit ribosome expression of the reporter genes in cells by the screening vector cloned with the short-chain IRES sequence; and (3) carrying out cell transfection on the screening vector cloned with the short-chain IRES sequence, screening out cells expressing reporter genes through cell sorting, and sequencing through a ribosome-newborn peptide chain compound to obtain the short-chain IRES sequence capable of recruiting ribosome to start circular RNA translation in the cells. According to the invention, a short-chain IRES sequence library is constructed, and short IRES capable of starting circular RNA translation is screened, so that transfection limitation caused by overlarge molecular weight of the current IRES sequence is overcome.

The present invention relates to a method for producing a circular gene of interest. A nucleic acid molecule comprising in the 5' to 3' direction a first bridging sequence and a gene of interest is provided. The first bridging sequence comprises a sequence corresponding to the 3' part of a ribozyme. A modified ribozyme comprising a truncated ribozyme which does not comprise the 3' part of the corresponding wild type ribozyme is also provided. The nucleic acid molecule and the modified ribozyme are combined under conditions suitable for circularization to occur. The invention also provides a modified ribozyme, a nucleic acid molecule and a kit.

The application belongs to the technical field of biological medicine, and discloses an in-situ vaccine type mRNA-tLNP preparation for solid tumor treatment and preparation and application thereof. The preparation is designed by double targets, so that CAR-T kills more tumor cells to overcome tumor heterogeneity, changes the tumor immune microenvironment through autocrine fusion proteins (anti-PD-1 scFv and TGFbetaRII, IL-15 and Flt3L, CD40L), promotes T cell proliferation, and recruits and activates dendritic cells, cross-presents new antigens in the tumor local part, and produces in-situ vaccination effects; circular RNA encoding the above proteins is prepared, and the circular RNA is wrapped by lipid nanoparticles modified by CD3 antibodies, so as to be directly delivered to the body, and a significant solid tumor treatment effect is produced.

The present application provides an engineered circular RNA capable of recruiting adenosine deaminase acting on RNA (ADAR; arRNA) and its application in treating Duchenne muscular dystrophy (DMD).

The invention belongs to the technical field of biological medicine. More specifically, the invention provides the annular RNACircMAP2, and the sequence of the annular RNACircMAP2 is as shown in SEQ ID NO. 1 or SEQ ID NO. 2. The invention proves that CircMAP2 can be used as a novel biomarker for diagnosing acute ischemic stroke for the first time. Compared with a traditional imaging diagnosis method, the acute ischemic stroke can be diagnosed by detecting the expression level of the CircMAP2 in the plasma and the plasma exosome of the patient, the cerebral infarction area of the acute ischemic stroke can be speculated through the expression level of the CircMAP2, and the method has the advantages of being easy and convenient to operate, high in detection speed and low in cost; the system is especially suitable for popularization and use in primary medical institutions. The product for diagnosing acute ischemic stroke provided by the invention can quickly and accurately diagnose acute ischemic stroke, and has good clinical popularization prospect and application value.

The application provides application of circular RNA_hsa_circ_0001681 in preparation of a marker for diagnosing malignant progression prognosis of a brain glioma patient, and the sequence of the circular RNA_hsa_circ_0001681 is shown as SEQ ID NO. 1. The application further provides a vector containing the sequence of the circular RNA_hsa_circ_0001681. The application further provides application of the above-mentioned vector in preparation of a drug for treating a brain glioma patient. The application further provides application of a reagent for detecting the circular RNA_hsa_circ_0001681 in preparation of a kit for diagnosing malignant progression prognosis of a brain glioma patient. Compared with normal brain glioma cells, the circular RNA is significantly decreased in common glioma cell lines, and cell experiments reveal that overexpression of the circular RNA_hsa_circ_0001681 can reduce malignant proliferation of glioma cells.

Provided herein are recombinant circular RNA (circRNA) molecules comprising an internal ribosome entry site (IRES) operably linked to a protein-coding nucleic acid sequence. The IRES may be, for example, a Type I IRES, such as a viral IRES. In some embodiments, the IRES is a synthetic IRES, such as an IRES comprising an aptamer. Methods of producing a protein in vitro or in vivo using the recombinant circRNA molecules are also provided.

The invention discloses a nucleotide for inhibiting expression of ILKAP (Interleukin-7-Kinase Associated Protein) related circular RNA (Ribonucleic Acid) and application of the nucleotide, and the nucleotide is characterized in that the nucleotide sequence is CGUCAGUACUCGGGUUUCA, and the expression level of hsacirc0001116 can be specifically and obviously reduced. Experimental results prove that the nucleic acid molecule can effectively interfere with the expression of hsacirc0001116 in human non-small cell lung cancer A549 cells, and can significantly inhibit the survival of lung cancer cells. In addition, when the nucleic acid molecule is combined with an existing antitumor drug for use, a synergistic treatment effect can be generated.

Provided is a method of using circular RNA as vaccine to treat cancer and design strategy to elicit specific and robust T cell response by promoting antigen presentation.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

Methods of delivering pharmaceutical compositions containing one or more nucleic acids via electroporation are disclosed. The methods include (i) delivering a pharmaceutical composition containing one or more nucleic acids to a target site of the subject; and (ii) electroporating the target site of the subject where the pharmaceutical composition was delivered. Electroporating the target site facilitates the uptake of the nucleic acids by and expression of an immunogenic protein in cells of the subject. Typically the nucleic acid is RNA such as non-replicating mRNA or circular RNA. The methods can deliver two or more nucleic acids, wherein at least one of the nucleic acids is an mRNA or a circular RNA. The disclosed methods are suitable treating or preventing the development of one or more symptoms of a disease or disorder such as an infection or cancer in a subject.

The invention belongs to the technical field of circular RNA, and discloses application of circular RNA derived from human pluripotent stem cell exosome in preparation of anti-inflammatory drugs for hepatic fibrosis. The invention relates to an application of human pluripotent stem cell exosome-derived circular RNA (Ribonucleic Acid) in preparation of an anti-inflammatory drug for hepatic fibrosis, in particular to CircBase ID of the circular RNA: hsacirc0076798. The human pluripotent stem cell exosome-derived circular RNA is circRNA in a human embryonic stem cell exosome, has the effects of regulating macrophage phenotype and inhibiting inflammatory response, and provides a thought and a method for preparing medicines for preventing and treating inflammation and reversing liver fibrosis. The circular RNA is used as a molecule for regulating and controlling gene expression of liver macrophages, and is expected to be used for preparing anti-inflammatory targeted drugs for hepatic fibrosis.

The invention belongs to the technical field of biological medicines, and particularly relates to a granzyme B expression system as well as a preparation method and application thereof. According to the invention, granzyme B with bactericidal activity is screened out, a corresponding expression vector is designed by adopting circular RNA, a bacterium-specific ribosome binding site (RBS) is taken as a protein translation regulation and control element, and a Lipid nano-particle (LNP) is taken as a delivery vector, so that efficient delivery of the circular RNA for coding GZMB and specific expression of GZMB in bacteria are realized. According to the strategy, efficient delivery and specific expression of circRNA for coding GZMB in bacteria are achieved, and a safe and accurate scheme is provided for GZMB antibacterial treatment.

This application discloses a circular RNA vaccine against porcine reproductive and respiratory syndrome (PRRS) virus, its construction method, and its application. The circular RNA vaccine comprises circular RNA and a pharmaceutically acceptable carrier. The coding elements in the circular RNA encode the GP4, GP2, GP5, and M proteins of PRRS virus. The circular RNA vaccine exhibits high stability and good safety, producing no adverse reactions after immunization of pigs. It induces high levels of neutralizing antibodies in pigs after immunization and activates a high level of cellular immune response, providing up to 100% immunoprotection. Furthermore, its preparation process eliminates the need for virus isolation, significantly shortening the research and development cycle. The production process is not constrained by biological factors such as virus titer, facilitating standardization and large-scale production, and effectively reducing production costs.